Clinical trial disruption concerns related to the COVID-19 pandemic topped across various geographies as the outbreak delayed or led to the suspension of enrolment for such trial programmes across the globe.

GlobalData conducted a poll to identify primary business concerns related to coronavirus outbreak in North America, Europe, Asia Pacific and Rest of the World (RoW).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Primary business concern related to COVID-19 by geography

Primary Business Concerns Related to the Covid-19 Outbreak by Geography 

Clinical trial disruption was the primary business concern according to a majority 28% of the respondents in Europe. The same opinion was shared by 26% of the respondents in North America, 26% in RoW and 20% in Asia Pacific.

Around 21% of the companies in North America noted that the safety of the patients recruited in the trials is their biggest concern. The figure stood at 20% in Europe, 16% in Asia Pacific and 14% in RoW.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Employee safety emerged as a major concern in Asia Pacific and RoW, according to 20% of the respondents each who expressed their apprehension about the well-being of their staff amid the pandemic. In Europe and North America, the figure stood at 16%.

The survey also found that concerns related to contract research organisations (CRO) disruptions are higher in Europe (14%) and North America (12%) than in Asia Pacific (7%) and RoW (6%).

Furthermore, the percentage of respondents who felt that the impact on supply chains is of the highest concern stood at 17% in RoW, 16% in Asia Pacific, 11% in North America and 8% in Europe.

Approximately 14% of the respondents in Asia Pacific opined that business development is the main concern, followed by 10% in North America, 8% in Europe and 6% in RoW.

Capital raising concerns were highest among respondents from the RoW (11%), followed by Asia Pacific (7%), North America (4%) and Europe (3%).

The analysis is based on responses received for Coronavirus Survey – COVID-19 and Decentralised Clinical Trials conducted by GlobalData between 04 June and 22 June 2020.